Elen Baloyan, MD is a clinical research physician at the Immune Oncology Research Institute and a clinical oncology resident at Yeolyan Hematology and Oncology Center, Yerevan State Medical University (YSMU). Elen graduated from YSMU in 2023 with a degree of honor and a full GPA-based scholarship. Her training is focused on medical oncology and areas of interest include lung cancer, immune oncology, global oncology, cancer molecular biology and access to care in LMICs. She joined IMMONC as project coordinator in 2023 and was clinical research fellow from 2024-2026. She is also the managing editor of OncoDaily since 2023, Editor-in-Chief of the OncoDaily Magazine, Director of the Boston Institute for Global Rankings (BIGR).
Elen is a member of ASCO, ESMO, ESO, IASLC, SIOP, POEM, AAHO, Young Oncologists of Armenia (YOGA), and is the first person from Armenia to have an oral presentation at the ASCO Annual meeting on disparities in immune-oncology clinical trials during the Global Oncology Community of Practice session. Her research has been selected as one of the best presenters during the CReDO 2026 workshop and is focused on increasing access to immunotherapy for patients with lung cancer in resource-limited settings. She is the lead author and co-author to articles published in peer-reviewed journals, authoring a book chapter on “Immune Checkpoint Inhibitors: Novel Therapies and Targets. In: Interdisciplinary Cancer Research. Springer” and Hematology Textbook for Yerevan State Medical University, during her first year of residency.
She is an alumnus of the Leadership Development and Innovations Academy of Armenia, where she completed a 6-month course focused on challenges and leadership to overcome them in healthcare. Besides her interest in oncology, Elen is committed to contributing to the development of the healthcare system in Armenia and globally, with the ultimate goal of making medical care accessible to everyone who may need it.
She is a co-investigator of the IMMONC0008 clinical trial launched by IMMONC in May 2024.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.